General Purposes The general purposes of the Committee are: • Oversee and monitor the establishment and maintenance by management of comprehensive safety, health, environmental, physical security and product stewardship policies, standards and practices for the Company, including risks related to such matters

KEY CHARACTERISTICS • Polymer colorants formulated specifically for healthcare product applications • Meets and exceeds various material performance requirements including FDA 21 CFR, ISO 10993 and USP Class VI • HC Plus colorants certified for bio-compatibility • Available as pre-color, concentrate, masterbatch or Smartbatch™ combined colorant/additive solution • Wide range of colors, striking special effects and custom color matching MARKETS AND APPLICATIONS OnColor™ HC and HC Plus Colorants are an excellent choice for medical devices and parts, pharmaceutical or cosmetic packaging, and many other healthcare related polymer applications.

KEY CHARACTERISTICS • Formulated specifically for healthcare product applications • Wide portfolio of polymer additive solutions, including: - Antimicrobial technology - Surface energy modification, including low retention - Authentication technology - Lasermarking - Sterilization and content protection - Processing optimization - FDA compliant resin and color changeover solutions • OnCap HC Plus certified for USP Class VI and ISO 10993 bio-compatibility requirements; includes anti-oxidant, lasermarking, antimicrobial, radiopacifier, anti-stat, and polymer and gamma stabilization performance additives OnCap™ HC & OnCap™ HC Plus Additives for Healthcare PRODUCT BULLETIN INDUSTRY SUPPORT • Supported with a broad range of technical support and services: - Restricted medical-grade raw material selection process - Sampling program - World-class FDA cGMP manufacturing facilities - Batch traceability and formulation lockdown systems - FDA Drug Master Files or Medical Device Files maintenance MARKETS AND APPLICATIONS OnCap HC and OnCap HC Plus Additives are an excellent choice for medical devices and parts, pharmaceutical or cosmetic packaging, and many other healthcare related polymer applications.

Plus précisément, Avient traite vos informations personnelles afin de pouvoir éventuellement conclure un contrat de travail ou toute autre relation contractuelle avec vous. Si vous êtes embauché, vos données sont transférées de la plateforme de recrutement au système d'administration des ressources humaines de l'entreprise Avient avec laquelle votre emploi ou votre relation de travail est formellement établi. Si vous êtes embauché, vos données seront transférées de la plateforme de recrutement au système d'administration des RH et à d'autres systèmes de la société Avient pour faciliter la relation de travail et/ou l'utilisation des systèmes de l'entreprise, de la société Avient respective avec laquelle votre relation de travail ou votre emploi est formellement établi.

Kunkle Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to be held on May 14, 2020: The proxy statement, proxy card and annual report to shareholders for the fiscal year ended December 31, 2019 are available at our Internet website, www.polyone.com, on the “Investor Relations” page. Independent Registered Public Accountant Services and Related Fee Arrangements AUDIT Report of the Audit Committee AUDIT The Audit Committee of the Board of Directors CORPORATE GOVERNANCE CORPORATE GOVERNANCE Director Independence Lead Director CORPORATE GOVERNANCE Board Leadership Structure Board’s Oversight of Risk Code of Ethics, Code of Conduct and Corporate Governance Guidelines CORPORATE GOVERNANCE Related Person Transactions Communication with Board Board and Committees Board Attendance CORPORATE GOVERNANCE Board Committees AAudit Committee – Primary Responsibilities and Requirements NUMBER OF MEETINGS IN 2019: 8 COMMITTEE MEMBERS: Compensation Committee – Primary Responsibilities and Requirements NUMBER OF MEETINGS IN 2019: 5 COMMITTEE MEMBERS: CORPORATE GOVERNANCE Governance and Corporate Responsibility Committee – Primary Responsibilities and Requirements NUMBER OF MEETINGS IN 2019: 2 COMMITTEE MEMBERS: CORPORATE GOVERNANCE Environmental, Health and Safety Committee – Primary Responsibilities and Requirements NUMBER OF MEETINGS IN 2019: 2 COMMITTEE MEMBERS: Board Refreshment and Diversity 0% 20% 40% 60% 80% 100% 5 or fewer 6 to 10 More than 10 Years of Service CORPORATE GOVERNANCE 3 of 10 Director nominees Diversity NON-EMPLOYEE DIRECTOR COMPENSATION 2019 NON-EMPLOYEE DIRECTOR COMPENSATION Non-Employee Director Compensation Highlights Non-Employee Director Retainer and Meeting Fees Role Annual Cash Retainers NON-EMPLOYEE DIRECTOR COMPENSATION 2019 Director Compensation Table Name Fees Earned or Paid in Cash (a) ($) Stock Awards (b) ($) Total (c) ($) (1) Fees Earned or Paid in Cash (column (a)) Stock Awards (column (b)) Option Awards Outstanding and Fully-Vested Deferred Shares Name Number of Deferred Shares(1) (#) OWNERSHIP OF POLYONE SHARES OWNERSHIP OF POLYONE SHARES Beneficial Ownership of Our Common Shares Name Number of Shares Owned(1) Right to Acquire Shares Total Beneficial Ownership % of Class(4) OWNERSHIP OF POLYONE SHARES Name and Address Number of Common Shares % of Class Stock Ownership Guidelines for Non-Employee Directors Delinquent Section 16(a) Reports COMPENSATION DISCUSSION AND ANALYSIS COMPENSATION DISCUSSION AND ANALYSIS Executive Summary Name Title How Pay is Tied to Company Performance. EXECUTIVE COMPENSATION Exercise or Base Price of Option Awards (column (i)) Grant Date Fair Value of Stock and Option Awards (column (j)) Narrative Disclosure Relating to the 2019 Summary Compensation Table and the 2019 Grants of Plan-Based Awards Table EXECUTIVE COMPENSATION Outstanding Equity Awards at 2019 Fiscal Year-End Option Exercise Price ($) (e) Option Expiration Date (f) Market Value of Shares or Units of Stock That Have Not Vested ($) (h) Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have Not Vested ($) (j) Name (a) Stock Awards Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) (d) Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that Have Not Vested (#) (i) Number of Shares or Units of Stock That Have Not Vested (#) (g) Number of Securities Underlying Unexercised Options (#) Unexercisable (c) Number of Securities Underlying Unexercised Options (#) Exercisable (b) Option Awardsp ( ) ( ) (j)( )( )( ) (g)( )( )( ) EXECUTIVE COMPENSATION Number of Securities Underlying Unexercised Options (#) Exercisable (column (b)) Number of Securities Underlying Unexercised Options (#) Unexercisable (column (c)) Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (column (d)) Option Exercise Price (column (e)) EXECUTIVE COMPENSATION Option Expiration Date (column (f)) Number of Shares or Units of Stock That Have Not Vested (column (g)) Market Value of Shares or Units of Stock That Have Not Vested (column (h)) Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (column (i)) Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (column (j)) 2019 Option Exercises and Stock Vested Name (a) Option Awards Stock Awards Number of Shares Acquired on Exercise (#) (b) Value Realized on Exercise ($) (c) Number of Shares Acquired on Vesting (#) (d) Value Realized on Vesting ($) (e) Stock Awards (columns (d) and (e)) EXECUTIVE COMPENSATION 2019 Nonqualified Deferred Compensation Name Aggregate Executive Registrant Aggregate Aggregate Aggregate Balance at Contributions Contributions Earnings Withdrawals/ Balance at 12/31/2018 in Last FY in Last FY in Last FY Distributions Last FYE ($)(1) ($)(2) ($)(3) ($)(4) ($) ($)(1)(5) EXECUTIVE COMPENSATION Potential Payments Upon Termination or Change of Control Summary of Potential Payments Management Continuity Agreements EXECUTIVE COMPENSATION Executive Severance Plan Long-Term Incentive Awards Retirement Benefits EXECUTIVE COMPENSATION Payments and Benefits Upon Termination — As of the End of Fiscal Year 2019 Name Benefits and Payments Voluntary Termination ($) Retirement (1) t ($) Disabilitytt ($) Death ($) Involuntary Termination with Cause ($) Involuntary Termination without Cause ($) vo u ta yvo u ta y Termination without Cause or for Good Reason Following a Change of Control ($)( )( )( )( )y ( )( )( )y EXECUTIVE COMPENSATION CEO Pay Ratio Disclosure CEO Annual Total Compensation for 2019: $6,106,632 Median Employee Annual Total Compensation for 2019: $53,371 Ratio of CEO to Median Employee Annual Total Compensation for 2019: 114:1 How the Median Employee was Determined in 2017 EXECUTIVE COMPENSATION Compensation Committee Interlocks and Insider Participation Risk Assessment of the Compensation Programs Compensation Committee Report The Compensation Committee of the Board of Directors MISCELLANEOUS MISCELLANEOUS PROVISIONS Voting at the Meeting nott Shareholder Proposals MISCELLANEOUS Proxy Solicitation We will furnish without charge to each person from whom a proxy is being solicited, upon written request of any such person, a copy of the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2019, as filed with the SEC, including the financial statements and schedules thereto.

Buyer intends that its indemnification obligations for claims related to or brought by anyone directly or indirectly employed by Buyer or its subcontractors will not be limited by any provision of any worker’s compensation act, disability benefit act or other employee benefit act, and Buyer hereby waives immunity under such acts to the extent it would bar recovery under or prevent enforcement of Buyer’s indemnification obligations. These Terms, together with (i) the product description, quantity, price, and payment terms stated on Seller’s order confirmation, (ii) any credit agreement, and (iii) the Specifications, if any, constitute the complete and final agreement and understanding between Seller and Buyer relating to the Product and supersede all prior oral or written communications, agreements, understandings, representations, statements, and assurances between the parties.

Ces relations sont importantes pour Avient et lui procurent des avantages considérables dans de nombreux secteurs d’activité. C’est pourquoi il est important qu’Avient fasse preuve de diligence raisonnable à l’égard des mandataires et d’autres tiers, tant avant que pendant la relation. Afin d’atténuer les risques, Avient doit tenir compte de certains facteurs avant d’entamer une relation avec un tiers.

Whether you’re designing for high-use, public devices or everyday home products that need to last longer, choosing the right material is more important than ever to minimize disinfectant-related failures, like cracking and crazing.

RECYCLING CHALLENGES As more and more PCR enters the value chain, brand owners, recyclers, and convertors are faced with new and increasing challenges related to recycling.

Toner make-up tanks should be placed conveniently close to the addition point in the PET production process and vessels, and pipework and ancillary equipment should be sized according to good practice engineering principles and in accordance with desired batch make up frequencies (related to plant size and production throughput).